On April 4, 2024, Aimed Alliance submitted a letter of support to the Colorado General Assembly urging the Committee to swiftly pass SB24-060, which would exempt Orphan Drugs from PDAB considerations. The letter supported exempting orphan drugs from affordability reviews and price setting, as this would help safeguard access, research, and investment in these treatments for individuals with rare diseases in Colorado. Read the letter here.
Last Updated on July 9, 2024 by Aimed Alliance
